Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes

NANot yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 15, 2025

Study Completion Date

September 30, 2026

Conditions
Osgood-Schlatter Disease
Interventions
OTHER

Urtica dioica cataplasm

Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.

OTHER

Placebo

Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.

DRUG

Vitamin D

Participants will receive oral vitamin D.

BEHAVIORAL

Resting conditions

Reduction in physical activity based on orthopedic advice.

All Listed Sponsors
lead

Faculty of Medicine, Sousse

OTHER

NCT07096037 - Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes | Biotech Hunter | Biotech Hunter